Welcome to our dedicated page for Autolus Therapeutics news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on Autolus Therapeutics stock.
Autolus Therapeutics plc reports news on its commercial-stage biopharmaceutical business developing, manufacturing and delivering next-generation programmed T cell therapies. Updates center on AUCATZYL (obecabtagene autoleucel, or obe-cel), product revenue, manufacturing capacity, gross margin plans and the company’s acute lymphoblastic leukemia business.
Company announcements also cover clinical programs using obe-cel and related T cell therapy candidates in pediatric relapsed/refractory acute lymphoblastic leukemia, lupus nephritis and progressive multiple sclerosis. Other recurring items include financial results, operational efficiency actions, investor presentations, Nasdaq inducement equity grants and ADR-related public-company disclosures.
Autolus Therapeutics (Nasdaq: AUTL) will release first quarter 2026 financial results and operational highlights before U.S. market open on May 14, 2026.
Management will host a conference call and webcast on May 14, 2026 at 8:30am EDT / 1:30pm BST to discuss results and provide a general business update; preregistration is required for dial‑in access and PINs.
Autolus (NASDAQ: AUTL) announced a strategic initiative to improve operational efficiency and reduce costs, including a workforce reduction of ~13% and doubled manufacturing for commercial and clinical patients in 2026. The company reiterated 2026 AUCATZYL net revenue guidance of $120–$135 million and expects a shift to positive gross margin in 2026. Actions are expected to reduce operating expenses by ~$15 million annually beginning 2027 and to incur ~ $8 million in restructuring charges, mostly recognized in H1 2026. Autolus expects cash runway into Q4 2027 based on current plans.
Autolus Therapeutics (Nasdaq: AUTL) granted inducement equity awards under its 2025 Inducement Plan on April 14, 2026. The Compensation Committee awarded options for 68,500 ADS and 57,765 RSUs to 15 employees, with options priced at $1.47 and ten-year terms.
Options vest over four years (25% after one year, then monthly over three years); RSUs vest in four equal annual installments. Awards are conditioned on continued service and were granted as inducements under Nasdaq Listing Rule 5635(c)(4).
Autolus Therapeutics (Nasdaq: AUTL) will participate in two investor conferences in April 2026. The CEO, Dr. Christian Itin, will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2028 at 10:15am EDT / 3:15pm BST. A webcast and 90-day replay will be available on the company's Events page. Management will also host investor meetings at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 16, 2026.
Autolus (NASDAQ: AUTL) reported Q4 2025 product revenue of $23.3M and full-year AUCATZYL net product revenue of $74.3M. The company forecasts $120M–$135M AUCATZYL revenue and a shift to positive gross margin in 2026, and expects cash to fund operations into Q4 2027.
Clinical programs advanced: pediatric B-ALL, lupus nephritis, progressive MS and AL amyloidosis; multiple initial data readouts expected by year-end 2026–2028.
Autolus Therapeutics (Nasdaq: AUTL) will release fourth quarter and full year 2025 financial results and operational highlights before U.S. market open on March 27, 2026. Management will host a conference call and webcast at 8:30am EDT / 12:30pm GMT to discuss results and provide a business update.
Participants must pre-register to receive dial-in numbers and a personal PIN. A simultaneous audio webcast and replay will be available on the company events website.
Autolus Therapeutics (Nasdaq: AUTL) will participate in two investor events in March 2026. The company will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2028 at 11:10am EST / 4:10pm GMT, with CEO Dr. Christian Itin presenting and a webcast available. A replay will be archived for 90 days. Management will host investor meetings at Jefferies Biotech on the Beach Summit on March 10, 2026 in Miami, FL.
Autolus Therapeutics (Nasdaq: AUTL) granted inducement stock options totaling 113,650 ADS to 22 employees under its 2025 Inducement Plan, with a grant date of January 26, 2026 and an exercise price of $1.46 per share. Each option has a 10-year term and vests over four years (25% after one year, then monthly over 36 months), subject to continued service. The awards were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Autolus (NASDAQ: AUTL) reported preliminary unaudited AUCATZYL® (obe-cel) net product revenue of approximately $24M for Q4 2025 and $75M for full-year 2025, and issued 2026 revenue guidance of $120M–$135M. Independent ROCCA real-world data confirmed strong clinical activity and a favorable safety profile. Key clinical updates include a 95.5% ORR in pediatric r/r B-ALL (CATULUS Phase 1) and selection of 50M cells as the Phase 2 dose in lupus nephritis (LUMINA). The company expects positive gross margin in 2026 and sufficient cash to fund operations into Q4 2027.
Autolus (NASDAQ: AUTL) will evaluate Cellares’ fully automated Cell Shuttle platform to complement commercial manufacturing of AUCATZYL® (obe-cel) at its Nucleus facility in Stevenage, UK.
The Cell Shuttle integrates CAR T unit operations in a single-use cartridge and can process up to 16 patient batches in parallel, with an architecture Cellares says can deliver up to 10-fold higher throughput versus conventional facilities. Cellares pairs this with Cell Q for automated, high-throughput QC and holds the FDA AMT designation.